Research Reference
Pemvidutide
Investigational GLP-1/glucagon dual agonist for obesity and MASH
Research & educational purposes only. BioMaxFit does not sell, promote, or represent peptides in any way. We are strictly educational and recommend working with your doctor on anything health-related. The information below comes from published research and documents what has been studied, not what should be done. Many of these compounds are investigational and not approved by the FDA; possession or use outside an authorized clinical trial may be illegal in your jurisdiction. This is not medical advice.
Pemvidutide is an investigational GLP-1/glucagon dual agonist being studied for obesity and metabolic-associated steatohepatitis. It is not FDA approved.
Dosing Reference
Reconstitution
Add 2 mL bacteriostatic water to the 10 mg vial. Resulting concentration: 5 mg/mL.
| Dose | Syringe Units | mL Volume | Schedule |
|---|---|---|---|
| 1.2 mg | 24 units | 0.24 mL | SubQ, once weeklyPhase 2 starting dose |
| 2.4 mg | 48 units | 0.48 mL | SubQ, once weeklyPhase 2 mid dose |
| 4.8 mg | 96 units | 0.96 mL | SubQ, once weeklyPhase 2 target dose |
Math assumes U-100 insulin syringes (1 mL = 100 units). Verify your syringe matches before use. Round half-units to the nearest visible mark.
Reconstitution
Pemvidutide (ALT-801) is an investigational GLP-1/glucagon dual receptor agonist (Altimmune) in phase 2 trials. It is supplied as a lyophilized vial for subcutaneous use. Compounded research-peptide forms are not FDA-approved.
For a compounded 10 mg vial reconstituted with 2 mL, the concentration is 5 mg/mL; a 2.4 mg dose draws to 48 units (0.48 mL) on a U-100 syringe. Store per manufacturer directions; compounded forms are not FDA-approved.
Cycling Protocol
Phase 2 trials (MOMENTUM for obesity) titrate pemvidutide weekly: 1.2 mg → 2.4 mg → up to 4.8 mg once weekly over several weeks, then maintained. No fixed cycle end; studied as chronic weekly therapy.
Routes of Administration
Subcutaneous injection (only established route): Once weekly into the abdomen, thigh, or upper arm. Any time of day, independent of meals.
No oral, intranasal, or intravenous route is established. Compounded forms are not FDA-approved.
Stacking Protocols
| Stack | Components | Purpose | | --- | --- | --- | | Dual agonist + Lifestyle | Pemvidutide + diet/exercise | Phase 2 obesity protocol |
Combining multiple GLP-1 agonists is not recommended. Pemvidutide is investigational and not FDA-approved.
Side Effects & Safety
- Nausea, vomiting, diarrhea, constipation — common, usually transient
- Hypoglycemia — risk, especially combined with insulin/sulfonylureas
- Pancreatitis — rare; discontinue if suspected
- Injection-site reactions — common
- Thyroid C-cell tumors — in rodents; avoid in MTC/MEN2 history
Pemvidutide is investigational (phase 2) and not FDA-approved. Compounded research-peptide forms are not FDA-approved.
Research Basis
Pemvidutide (ALT-801) is an investigational GLP-1/glucagon dual receptor agonist (Altimmune), a balanced oxyntomodulin analog.
Mechanism: Balanced GLP-1 and glucagon receptor agonism — appetite suppression and insulin secretion (GLP-1) plus increased energy expenditure and hepatic fat oxidation (glucagon), targeting weight loss and MASH.
Clinical evidence: Phase 2 MOMENTUM trial demonstrated significant weight loss; phase 2b in MASH ongoing. Not FDA-approved.
Investigational — not FDA-approved. Compounded research-peptide forms are not FDA-approved.